Publications by authors named "Libby Stein"
Background: Non-invasive tests, such as Fibrosis-4 index and transient elastography (commonly FibroScan), are utilized in clinical pathways to risk stratify and diagnose non-alcoholic fatty liver disease (NAFLD). In 2018, a clinical decision support tool (CDST) was implemented to guide primary care providers (PCPs) on use of FibroScan for NAFLD.
Aim: To analyze how this CDST impacted health care utilization and patient outcomes.
Despite growing interest in remote patient monitoring, limited evidence exists to substantiate claims of its ability to improve outcomes. Our aim was to evaluate randomized controlled trials (RCTs) that assess the effects of using wearable biosensors (e.g.
View Article and Find Full Text PDFArticle Synopsis
- Integrase-defective lentiviral vectors (IDLVs) struggle to effectively deliver zinc finger nucleases (ZFNs) to human cells due to low gene expression, often influenced by epigenetic silencing.
- In this study, the HDAC inhibitor valproic acid (VPA) was tested and found to enhance ZFN expression from IDLVs by up to three times in K562 cells, leading to better disruption of the ADA gene.
- Other FDA-approved HDAC inhibitors also showed similar benefits in increasing ZFN activity in both K562 and primary human CD34(+) cells, with cell cycle modulation identified as a major driver for improved gene expression.